Předmět: |
|
Zdroj: |
Immunotherapy Weekly; 12/3/2024, p352-352, 1p |
Abstrakt: |
Research conducted at the Instituto Nacional de Enfermedades Respiratorias in Mexico City focused on the role of CD155 in lung adenocarcinoma. The study found that interleukin-6 (IL-6) and suppressor of cytokine signaling 1 (SOCS1) are critical regulators of CD155 expression in lung adenocarcinoma. The researchers suggest that further studies are needed to understand the impact of these molecules on tumor development and to enhance their clinical use as biomarkers and targets for immunotherapies. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|